Prospectus filed for resale of 75.1M shares, enabling massive dilution from recent private placement

summarizeZusammenfassung

This 424B3 prospectus supplement enables the resale of a substantial number of shares by investors, including those from a private placement announced in a concurrent 8-K. The total shares registered for resale, 75.1 million, significantly exceeds the company's current outstanding share count of 73.5 million, indicating massive potential dilution for existing shareholders. While the underlying private placement provides critical capital for the micro-cap life sciences company (up to $16.58 million, or 55% of its market cap), the immediate registration for resale by selling stockholders creates a significant overhang on the stock. This event follows recent shareholder approval for a reverse stock split, likely aimed at regaining Nasdaq compliance, making the timing of this dilutive event particularly challenging for investor sentiment.

check_boxSchlusselereignisse

• Massive Share Resale Registered

  Selling stockholders registered up to 75.1 million shares of common stock for resale, including shares and warrants from a private placement dated February 19, 2026.

• Significant Dilution Potential

  The shares registered for resale represent over 100% of the company's 73.5 million outstanding shares as of February 20, 2026, indicating substantial potential dilution for existing shareholders.

• No Direct Proceeds to Company from Resale

  Klotho Neurosciences will not receive any proceeds from the sale of shares by the selling stockholders, though it will receive proceeds if warrants from the private placement are exercised.

• Follows Recent Capital Raise at Discount

  This resale prospectus follows a definitive agreement for a private placement where the company agreed to sell 34.55 million shares and an equal number of warrants at an average price of $0.24 per share, a significant discount to the current market price of $0.38.

auto_awesomeAnalyse

This 424B3 prospectus supplement enables the resale of a substantial number of shares by investors, including those from a private placement announced in a concurrent 8-K. The total shares registered for resale, 75.1 million, significantly exceeds the company's current outstanding share count of 73.5 million, indicating massive potential dilution for existing shareholders. While the underlying private placement provides critical capital for the micro-cap life sciences company (up to $16.58 million, or 55% of its market cap), the immediate registration for resale by selling stockholders creates a significant overhang on the stock. This event follows recent shareholder approval for a reverse stock split, likely aimed at regaining Nasdaq compliance, making the timing of this dilutive event particularly challenging for investor sentiment.